文献速递认知障碍与痴呆

向无认知障碍研究参与者披露淀粉样蛋白影像结果的短期心理结局

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
PubMed 文献 · JAMA Neurol · 2020-01-01

elevated组与not elevated组在抑郁、焦虑、自杀意念评分变化上无显著差异;elevated组对AD担忧增加,not elevated组未来时间感略增。

要点

  • 披露淀粉样蛋白升高结果未导致短期抑郁、焦虑或自杀风险增加。
  • 淀粉样蛋白升高者仅对AD的担忧评分轻度增加,无临床显著心理危害。
  • 结果支持在临床研究中向无认知障碍者安全披露生物标志物结果。

核心结论

  • 在无认知障碍的临床前AD研究参与者中,得知淀粉样蛋白升高未导致短期负面心理后遗症。

研究设计与样本

  • 观察性研究,纳入1167例淀粉样蛋白升高和538例未升高参与者,年龄65-85岁,无已知认知障碍。
  • 参与者接受淀粉样蛋白PET扫描并通过预设流程获知结果,包括扫描前教育和心理评估。

临床怎么用

  • 在无认知障碍人群中披露淀粉样蛋白PET结果时,短期心理风险较低,可参考预设教育流程实施。
  • 需关注淀粉样蛋白升高者对AD的担忧增加,但无需常规筛查短期抑郁焦虑。

局限性

  • 研究为观察性设计,参与者来自临床试验筛选人群,结果外推需谨慎。
  • 样本以白人、非拉丁裔为主,心理结局评估时间较短,长期影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. OBJECTIVE: To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography results to older adults who did not have cognitive impairment. DESIGN, SETTING, AND PARTICIPANTS: This observational study included participants who were screening for a multisite randomized clinical trial that began on February 28, 2014, and is anticipated to be completed in 2022. Participants aged 65 to 85 years who had no known cognitive impairments underwent an amyloid positron emission tomography scan and learned their result from an investigator who used a protocol-specified process that included prescan education and psychological assessments. This report compares participants with elevated amyloid levels with at least 1 available outcome measure with participants who did not have elevated amyloid levels who enrolled in an observational cohort study and received further evaluations. Data were collected from April 2014 to December 2017 and analyzed from March 2019 to October 2019. EXPOSURES: A personal biomarker result described as either an elevated or not elevated amyloid level. MAIN OUTCOMES AND MEASURES: To assess the immediate and short-term psychological outcome of disclosure, the following validated measures were used: the Geriatric Depression Scale, the state items from the State-Trait Anxiety Inventory, and the Columbia Suicide Severity Rating Scale, as well as the Concerns About AD Scale and the Future Time Perspective Scale to assess changes in participants' perceived risk for AD and perceived remaining life span, respectively. RESULTS: A total of 1167 participants with elevated amyloid levels and 538 participants with not elevated amyloid levels were included. Participants had a mean (SD) age of 71.5 (4.7) years, 1025 (60.1%) were women, and most were white (1611 [94.5%]) and non-Latino (1638 [96.1%]). Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67). Participants with elevated amyloid levels had increased Concern About AD scores (raw change in scores: elevated amyloid group, 0.8 [3.9]; not elevated amyloid group, -0.4 [3.8]; P < .001). Participants with not elevated amyloid levels experienced a slight increase in Future Time Perspective score(mean [SD] score, 1.15 [7.4] points; P < .001); there was no change in time perspective among those receiving an elevated amyloid result (mean [SD] score, 0.33 [7.8] points). CONCLUSIONS AND RELEVANCE: In this observational preclinical AD study, participants who learned they had elevated amyloid levels did not experience short-term negative psychological sequelae compared with persons who learned they did not have elevated amyloid levels.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Grill JD, Raman R, Ernstrom K, et al. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020. PMID: 32777010. doi:10.1001/jamaneurol.2020.2734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。